The successful re-opening of a blocked coronary artery has a beneficial effect on the further clinical course (e.g. improvement of clinical symptoms, improved quality of life, increased heart function, etc.). However, some types of blockages are more difficult to open by means of percutaneous coronary intervention (PCI), a procedure which is commonly used for these kind of problems. This procedure makes use of a technique in which special wires, balloons, stents (metal or polymeric tube-like structures) and devices are utilized to re-open or revascularize a blockage in one of the blood vessels of the heart. This type of blockages are chronic total occlusions (CTO). CTOs have certain characteristics which impede the revascularization of the blood vessel. Nevertheless, remarkable progress has been achieved over the past few years in the area of CTO revascularization or CTO PCI. A large range of CTO dedicated materials, such as guidewires, guiding catheters, devices, balloons and stents, as well as different techniques have been developed. However, at present, reluctance to open CTOs still exists, due to the indications and outcomes of percutaneous revascularization as well as the technical difficulties which commonly arise during these interventional procedures. The presence of these difficulties results in suboptimal success rates worldwide (±70-80%), despite these many innovations. To increase these success rates and to make sure more interventional cardiologists will treat CTOs, a hybrid treatment algorithm has been developed with the materials (e.g. CrossBoss™ catheter; Bridgepoint Medical, Inc.) and techniques, currently already available. The main purpose of this study is to evaluate the efficacy and efficiency of this hybrid algorithm as well as validating the efficacy of one of the materials (CrossBoss™ catheter), used in this algorithm. To be able to do this, data concerning the patients' demographics, CTO characteristics, procedure and outcome will be collected in the form of a registry. This registry will be performed in several European centra (Belgium, the Netherlands, United Kingdom, France). Since the study will only collect data and no intervention is performed, this will be an observational study. At regular time points, the data will be checked for errors or inconsistencies. To do this, site visits will be performed at pre-defined times.
Study Type
OBSERVATIONAL
Enrollment
1,177
Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
UZ Brussel
Brussels, Limburg, Belgium
Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium
Hasselt University
Hasselt, Limburg, Belgium
Groupe Hospitalier Mutualiste (GHM)
Grenoble, France
Clinique de Marignane
Marignane, France
Nouvelles Cliniques Nantaises (NCN)
Nantes, France
Hôpital Nord - CHU de St Etienne
Saint-Priest-en-Jarez, France
Onze-Lieve-Vrouwe Gasthuis (OLVG)
Amsterdam, Netherlands
Catharina Ziekenhuis
Eindhoven, Netherlands
Erasmus MC
Rotterdam, Netherlands
...and 11 more locations
Outcome of CTO PCI procedure
Description: Success percentage of the hybrid algorithm and of those procedures in which CrossBoss™ and Stingray™ technologies are used (as a stand alone device or combined with other techniques) in CTO lesions according to the Japanese scoring system (J-CTO). Success is defined as successful revascularization, resulting in TIMI flow 3.
Time frame: after 3 hours
Outcome of PCI procedures in which CrossBoss™ technology is used (as a stand alone device)
Outcome (success/failure) of PCI procedures in which CrossBoss™ technology is used (as a stand alone device).
Time frame: after 3 hours
Outcome of PCI procedures in which CrossBoss™ technology is used (combined with other techniques).
Outcome (success/failure) of PCI procedures in which CrossBoss™ technology is used (combined with other techniques)
Time frame: after 3 hours
Complications
Complications (either CrossBoss™/Stingray™ related or not): Major Adverse Cardiac Events (MACE) during in-hospital stay (approximately 1-2 days) and at follow-up (first month after CTO PCI). MACE is common endpoint for death, Q-wave myocardial infarction (MI) (according to ESC guidelines), non Q-wave MI (according to ESC guidelines) and target vessel revascularization. Other complications include target vessel failure (i.e. applies when target vessel is occluded at follow-up (first month after CTO PCI) but no revascularization has been considered), tamponade, perforation, bleeding requiring transfusion/surgery, peri-procedural infarction ((N-)STEMI) (according to ESC guidelines) and loss of side-branches.
Time frame: up to month 1
Clinical status after PCI procedure
Record medical drug prescription (after CTO PCI) and clinical status during in-hospital stay and during follow-up (1 month).
Time frame: up to month 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.